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Abstract
Background:  Imaging tools such as scanning electron microscope (SEM) and atomic force
microscope (AFM) can be used to produce high-resolution topographic images of biomedical
specimens and hence are well suited for imaging alterations in cell morphology. We have studied
the correlation of SMAR1 expression with cell surface smoothness in cell lines as well as in different
grades of human breast cancer and mouse tumor sections.
Methods: We validated knockdown and overexpression of SMAR1 using RT-PCR as well as
Western blotting in human embryonic kidney (HEK) 293, human breast cancer (MCF-7) and mouse
melanoma (B16F1) cell lines. The samples were then processed for cell surface roughness studies
using atomic force microscopy (AFM) and scanning electron microscopy (SEM). The same samples
were used for microarray analysis as well. Tumors sections from control and SMAR1 treated mice
as well as tissues sections from different grades of human breast cancer on poly L-lysine coated
slides were used for AFM and SEM studies.
Results: Tumor sections from mice injected with melanoma cells showed pronounced surface
roughness. In contrast, tumor sections obtained from nude mice that were first injected with
melanoma cells followed by repeated injections of SMAR1-P44 peptide, exhibited relatively
smoother surface profile. Interestingly, human breast cancer tissue sections that showed reduced
SMAR1 expression exhibited increased surface roughness compared to the adjacent normal breast
tissue. Our AFM data establishes that treatment of cells with SMAR1-P44 results into increase in
cytoskeletal volume that is supported by comparative gene expression data showing an increase in
the expression of specific cytoskeletal proteins compared to the control cells. Altogether, these
findings indicate that tumor suppressor function of SMAR1 might be exhibited through
smoothening of cell surface by regulating expression of cell surface proteins.
Conclusion: Tumor suppressor protein SMAR1 might be used as a phenotypic differentiation
marker between cancerous and non-cancerous cells.
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Background
Even though the current diagnosis of cancer depends
mainly upon tissue biopsy inspection by routine optical
microscopy [1], imaging tools such as scanning electron
microscope (SEM) and atomic force microscope (AFM)
can provide a better understanding of the surface details at
the nanometer level. This will avoid possible ambiguity
that may be imposed due to diffraction limitations (~250-
300 nm) posed by light microscopy [2-5]. Despite high-
resolution imaging obtained by electron microscopy, it
lacks certain advantages, such as making precise structural
measurements along the z-axis, that are provided by scan-
ning probe microscopy, especially AFM. The two com-
monly used analytical techniques for high resolution
surface imaging of materials is the SEM and AFM. Both
these tools provide topographical information at a resolu-
tion far superior to optical methods [6,7]. Scanning elec-
tron microscope can be used to image topography of the
sample or to determine the local composition, crystal
structure, orientation, electrical and optical properties of
the sample [8,9].
AFM is a probing-based instrument [6] that has gained sig-
nificant importance in the recent years for studying bio-
logical samples at sub-nanometer scale in their natural
aqueous environment [10-12]. The vertical resolution is
mostly determined by the AFM scanner sensitivity, and is
as high as 0.01 nm. Besides topography-based studies,
due to its high sensitivity, AFM is being widely used to
study receptor-ligand interactions, protein unfolding and
cell adhesion [13-19]. AFM imaging is now being com-
bined with fluorescence microscopy to study different cel-
lular structures [20-22]. Due to application of low forces
with minimal disruption to cells [23,24], AFM has been
used to probe a number of inherent properties of micro-
bial cells [25,26], mammalian cells and biomolecules
apart from analyzing cellular mechanical strain and elas-
ticity [15,27-33]. Apart from its use in probing cellular
mechanics under physiological conditions, it has been
recently used for nanomechanical analysis of live meta-
static cancer cells from body fluids of patients suspected of
suffering from various cancers [34].
In the present work, we are for the first time reporting the
morphological differences between cancerous cell lines
and cells overexpressing a tumor suppressor protein,
SMAR1 (Scaffold/Matrix Associated Region binding pro-
tein 1) by utilising the nanoscale capabilities of both SEM
and AFM. SMAR1, a matrix associated region binding pro-
tein (MARBP) [35] functions as a potent tumor suppressor
through interaction with and activation of p53 ultimately
resulting into G2/M arrest of the cells [36,37]. Interest-
ingly, we have recently shown a drastic downregulation of
SMAR1 in higher grades of human breast cancers [38].
Besides tumor suppressor function, SMAR1 controls T cell
development through regulation of TCRβ transcription by
modulating Eβ enhancer and TCRβ gene rearrangement
[39,40]. SMAR1 interacts with a MARBP, Cux/CDP, and
both synergistically regulate the TCRβ gene transcription
[40]. Being a transcriptional repressor, SMAR1 has also
been shown to repress cyclin D1 gene expression [41],
whose higher expression is a hallmark in breast cancer.
Since SMAR1 expression is decreased in majority of can-
cerous cells [36] and it has been shown to disrupt the
tumor vasculature [42], we were interested in studying
detectable phenotypic differences between the cells over
expressing or under expressing SMAR1.
SEM and AFM imaging studies on HEK 293 as well as
B16F1 cell lines, revealed a rough cell surface architecture.
Interestingly, we found that upon overexpression of
SMAR1, the cells showed smooth topographic features.
These results were in concurrence with the data obtained
from different grades of human breast cancer tissue sec-
tions. We have recently shown that with the advanced
stages in breast cancer, SMAR1 expression level goes down
[38]. Here, we have further illustrated that in advanced
stages of breast cancer, the morphology of the cells
become rough compared to the smooth surface feature of
cells from tissue sections of adjacent normal globular
breast area. Moreover, we also observed that topography
of cells from tumor sections of mice injected with
melanoma cells (B16F1) were rough compared to the cells
from tumor sections of mice injected first with B16F1 cells
followed by SMAR1-P44 peptide treatment. Further, by
using AFM, we demonstrated that the cytoskeletal volume
of cells (calculated from 'flooding/find hills' options in
the WSxM software by Nanotec Electronica) overexpresss-
ing SMAR1 was almost 3.5 folds more compared to the
control cells. This is supported by data from microarray as
well as mRNA expression studies that too exhibited
increased expression of certain cytoskeletal proteins as
well as few adhesion molecules in SMAR1 overexpressing
cells. These results suggest that SMAR1 plays a key role in
maintaining cellular topography through regulation of
specific cytoskeletal proteins and this feature could be
explored for phenotypic distinction between cancerous
and non-cancerous cells.
Methods
Cell culture and transfection
Human embryonic kidney (HEK) 293, mouse melanoma
(B16F1) and human breast cancer (MCF7) cell lines were
grown in DMEM supplemented with 10% FBS in the pres-
ence of 5% CO2 at 37°C. Around 3 × 105 cells were plated
on coverslips in 35 mm culture dishes. After 24 h, cells
were transiently transfected using lipofectamine-2000
with SMAR1 cDNA full-length constructs from pBK-CMV
(pBK-CMV-SMAR1) expression plasmid (1.0 μg) [36] or
with 100 nM of custom synthesized SMAR1-siRNA oligo-
nucleotides (Ambion Inc., Austin, TX) [37]. Forty eightBMC Cancer 2009, 9:350 http://www.biomedcentral.com/1471-2407/9/350
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hours post-transfection, the cells were processed for either
SEM or AFM analysis.
RT-PCR
The control cells as well as cells transfected with either
full-length SMAR1 construct or SMAR1-siRNA oligonucle-
otide were harvested and total RNA was isolated that was
subjected to cDNA synthesis following the manufacturer's
instruction (Invitrogen). PCR was done using specific
primers for SMAR1: F-5'-GCATTGAGGCCAAGCTGA
AAGCTC-3' and R-5'-CGGAGTTCAGGGTGATGAGTGT-
GAC-3'; NEU: F-5'-ACCCATTAGCCAGACCACAG and R-
5'-GGCTACTATCCCAACGACCA; MARK1: F-5'-CAC TCT-
TCAGTCCCCTGCTC and R-5'-CAACTGTTGTGCTGC
CAAGT; MYH10: F-5'-GTACCTTGCCCATGTTGCTT and
R-5'-TTTTGCTTGAGCAACAGCAC; and β-actin F-5'-TAC-
CACTGGCATCGTGATGGACT-3' and R-5'-TTTCTGCATC-
CTGTCGGAAAT-3'.
Western Blotting
For western blotting, the control cells as well as cells trans-
fected with either full-length SMAR1 construct or SMAR1-
siRNA oligonucleotide were harvested, washed with 1×
PBS and lysed in buffer as described earlier [37]. SMAR1
polyclonal antibody that was raised in house [41] was
used for probing the blot.
Histological sections
Mouse tumor sections used for SEM as well as AFM studies
were obtained by establishing tumors in nude mice
treated with either control B16F1 mouse melanoma cells
or with SMAR1-P44 peptide [42]. Briefly, nude mice were
subcutaneously injected with 2 × 106 B16F1 cells and once
the tumors were clearly visible, SMAR1-P44 peptide was
subcutaneously injected proximal to the tumor sites at a
dose of 200 μg/ml/mouse three times a week. The treat-
ment was continued for 4 weeks. For control experiments,
B16F1 cells alone were subcutaneously injected into the
mice and were monitored for tumor growth [42]. In each
set of experiments, five mice were used and the mice were
maintained under pathogen-free conditions. All the mice
experiments were carried out with an approval from the
Institutional (NCCS, Pune) Ethical as well as Biosafety
Committee. Human breast cancer samples were classified
into Infiltrating Ductal Carcinoma Grade I, II and III (IDC
G I, II and III) by standard HE staining [38]. For compar-
ison, adjacent normal globular tissue area was taken as
normal control. Human breast cancer tissue sections were
obtained from KEM hospital, Pune upon approval from
Hospital Ethical Committee.
Atomic force microscopy
For AFM measurements, the control cells as well as cells
transfected with either SMAR1 or SMAR1-siRNA were
fixed with 2.5% paraformaldehyde for 15 min, followed
by washing twice with 1× PBS and twice with glass dis-
tilled water before AFM measurements (the last wash with
glass distilled water was done because PBS forms crystal-
like structures upon drying that results into artifacts).
Breast carcinoma tissues used in the study had been
obtained from KEM Hospital, Pune and the histological
grading of tumor tissues was done following modified
Bloom and Richardson guidelines. For AFM studies, the
tumor sections in paraffin-embedded blocks were trans-
ferred to poly-L-lysine-coated glass slides and air-dried
overnight at 37°C. They were dewaxed in xylene (three
changes) and rehydrated in a graded series of decreasing
ethanol concentration before subjecting for AFM imaging.
The surface topography of cells as well as tumor histolog-
ical sections obtained from nude mice and breast cancer
patients was imaged using Multiview 1000™ AFM
(NANONICS, Jerusalem, Israel) operating in amplitude
modulated tapping mode. Glass fiber probes (NANON-
ICS, Jerusalem, Israel), with a tip diameter (Φ) of 20 nm
and nominal spring constant (k) of 10 N/m were used at
a low resonance frequency (ωo) of 80 KHz. All AFM exper-
iments were performed in air at ambient temperature. The
surface of the cells was scanned in the x, y and z directions
by a sharp tip, and moved by a piezoelectric translator. A
laser beam reflected off the cantilever towards a four-seg-
ment photodiode sensed the deflection of the cantilever
when the tip scanned the sample surface. All the images
were acquired with a 512 × 512 data point resolution and
a scan delay of 5 ms.
Roughness analysis
The roughness of the surface of all the cells was analyzed
as described earlier [43] by measuring the root mean
square roughness, Rrms, on the height image, which is
defined as the standard deviation from the mean data
plane of the h (height) values of the AFM images within a
selected region on the cell surface:
where hi is the current height value;  , the height of the
mean data plane; and N, the number of points within the
selected region of a given area. The roughness analysis was
carried out on raw AFM images after normalization. For
roughness analysis, four different cells from each group
were taken and four different areas from each cell were
chosen to calculate Rrms. The areas chosen were 50 × 50
data points in dimension. The overall weighted mean sur-
face roughness   was calculated as:
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where   is the mean of the four values on each cell
i, and each mean   value is weighted by a factor 1/
σi
2 where σi
2 is its standard deviation. The overall standard
deviation, σ, of the best estimate  , is given by:
Scanning electron microscopy
For SEM analysis, the control cells as well as those trans-
fected with SMAR1 were processed for fixation wherein
they were rinsed twice with phosphate buffered saline
(PBS) followed by washing in buffer A (20 mM HEPES,
100 mM KCl, 2 mM MgCl2, pH 7.0). This was followed by
incubation for 20 min with 2.5% p-formaldehyde in
buffer A at 4°C. After extensive rinsing with buffer A, cells
were dehydrated through increasing concentrations of
ethanol (50, 70, 90 and 100%). Samples were dried and
sputter coated with ~5 nm platinum. The field emission
scanning electron microscope (JEOL, USA, JSM 6360) was
operated at 10 kV.
Cytoskeletal preparation for the imaging
HEK 293 cells (control and SMAR1 transfected), grown on
coverslips were washed twice with Hank's Balanced Salt
Solution (HBSS) solution. The cells were then treated for
5 min at room temperature with a buffer (10 mM Tris-
HCl, pH 7.6, 0.14 M NaCl, 5 mM MgCl2, 4% polyethylene
glycol 6000) containing 0.5% Triton X-100 detergent
(Sigma) [44]. After the treatment, the cells were washed
twice for 2 min in the buffer alone and then fixed in the
buffer containing 1% formalin for 10 min. The treating
solution was removed and the cells were washed twice
with HBSS solution. For scanning in air, the cells were
washed with MilliQ ultrapure water and dried under
ambient conditions (24°C, 48% humidity). The cells
were imaged immediately after treatment.
Microarray analysis
Microarray was performed on B16F1 control and SMAR1-
stably transfected cells as well as on HEK 293 control cells
and those treated with SMAR1-P44 peptide [41]. The
experiment was commercially performed by Agilent Gen-
otypic Technology (Bangalore, India).
Results
Cells overexpressing SMAR1 exhibit smooth topography: 
SEM study
SMAR1 functions as a tumor suppressor protein that
upregulates p53 along with a number of cell cycle regula-
tory proteins ultimately resulting into tumor retardation
[36,37]. To determine if there are any discernible pheno-
typic differences between cancerous cells and cells overex-
pressing SMAR1, we utilized both SEM and AFM.
Different cell lines: HEK 293, B16F1 and MCF7 (data not
shown) were used in the study. The cells were transiently
(HEK 293 and MCF7) or stably (B16F1) transfected with
SMAR1 (full-length) and SMAR1-siRNA (in HEK 293
cells). The overexpression of SMAR1 was confirmed by
RT-PCR (Fig. 1B) and western blot (Fig. 1C) in HEK 293
cells. SMAR1-siRNA treated cells showed a significantly
reduced expression of SMAR1 compared to the control
cells. SEM analysis of cells overexpressing SMAR1 (Fig. 1A,
photographs taken at 8500 × magnification) exhibited
smoother topography compared to either control cells or
those treated with SMAR1-siRNA that exhibited rough
surface features. Similar results were found in B16F1 cells
wherein the morphology of control cells (Fig. 1D, upper
panel; photographs taken at 3000 × and 8000 × magnifi-
cation) was rough compared to SMAR1 stably transfected
cells (Fig. 1D, lower panel; photographs taken at 3000 ×
and 8500 × magnification). MCF7 cells also exhibited
similar results wherein the morphology of SMAR1 treated
cells was smoother compared to the control cells (data not
shown).
Since SMAR1 is downregulated in majority of cancers
[36], we determined the morphology of cells isolated
from tumors raised in nude mice and compared them
with tumors isolated from SMAR1-chimera peptide
treated mice. For this, nude mice were injected with
mouse melanoma cells (B16F1) to develop subcutaneous
tumors [42]. In the test group, the mice that had been
injected with B16F1 cells were given repeated doses of
SMAR1-P44 peptide to retard the tumor growth. SMAR1-
P44 is a 33-mer peptide of SMAR1 that retains the tumor
suppressor function of full-length protein [42]. Since the
treated mice exhibited inhibition of tumor growth, we
used tissue sections from those tumors for SEM as well as
AFM studies. As expected, SEM study showed that tumor
sections from SMAR1-P44 treated mice (Fig. 2A, lower
panel, photographs taken at 3300 × and 12000 × magni-
fication) exhibited much smoother topography compared
to the tumor sections from control mice (Fig. 2A, upper
panel, photographs taken at 3300 × and 12000 × magni-
fication). Since SMAR1 expression is known to be down-
modulated in different cell lines [36], particularly breast
cancer cells [38], we were interested in detecting pheno-
typic differences between normal and cancerous cells iso-
lated from human subjects. For this, we obtained tissue
sections from normal adjacent globular breast tissue and
cancerous tissue from patients having different grades of
breast cancer (Infiltrating Ductal Carcinoma (IDC) Grade
I, II and III) [38]. It was observed that with increasing
stages of cancer (from Grade I to Grade III), the surface
roughness of the cells increased compared to the sections
from normal breast tissue that had much smoother topog-
raphy (Fig. 2B). Moreover, it was observed that the giant
multinucleate cells exhibited significantly rough mor-
phology compared to either normal or different grade
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tumor sections. Photographs have been taken at 1000 ×,
3000 × and 8500 × magnification for all the tissue sec-
tions. For better clarification of the difference between cell
surface roughness of normal breast tissue versus grade I
breast tumor, we have taken pictures at 27000 × magnifi-
cation showing a remarkable difference in the cell surface
topology between the two (Fig. 2C).
AFM study confirms the smooth surface profile of SMAR1 
overexpressing cells
AFM provides tri-dimensional high-resolution informa-
tion about the surface of a sample, and thus cannot give
any direct information about the interior of a cell. The
AFM shows the topography (height), processed, 3D and
profile images of the cells. The height range over the
whole cells is usually several microns, so the 3D topogra-
phy image shows the overall height of the cells. The proc-
essed signal image gives the information about the fine
details of the cell structure. The processed images clearly
show the smallest and sharpest features of the cell surface.
It was observed that in each cell line tested, HEK 293 (Fig.
3A) and B16F1 (Fig. 3B), the surface topography of con-
trol and SMAR1-siRNA treated (in HEK 293 cells only)
was rougher when compared to SMAR1-treated cells (Fig.
3A, 3B). The profile images of control and siRNA treated
cells were irregular whereas SMAR1-treated cells exhibited
relatively regular surface profile with small overall height
modulations. Similarly, tumor sections from mice
injected with B16F1 cells showed pronounced surface
roughness compared to the tissue sections derived from
mice treated with SMAR1-P44 peptide (Fig. 4A).
Earlier it been has shown that SMAR1 is drastically down-
regulated in higher grades of breast cancer [38]. The same
sections corresponding to various grades of breast cancer
were used to study the difference in surface topology of
different grades of breast cancer. Upon comparison of tis-
sue sections from normal breast tissue with those from
different grades of breast cancer (Fig. 4B), we observed
that the former exhibited smoother surface architecture
compared to the latter.
The statistical distribution of the mean roughness 
(i = 1, 2, 3, 4) was determined on control as well as
SMAR1-treated cells from each cell line [HEK 293, B16F1
and MCF7 (data not shown)] (Fig. 3A, 3B, respectively), as
well as histological sections (mouse as well as human; Fig.
4A and 4B, respectively), which showed that the mean
roughness was centered on the weighted mean surface
roughness,  , as reported in Tables 1 and 2. Control
cells of HEK 293 and B16F1 showed 1.7-fold and 1.4-fold,
increase in surface roughness, respectively, compared to
their respective SMAR1-overexpressed cells (Table 1).
Likewise, tumor sections from control mice exhibited 2-
fold increase in surface roughness than SMAR1-P44 pep-
tide treated mice (Table 1). Interestingly, in histological
sections from human breast cancer tissue, it was observed
that with increase in the grade of cancer, there was an
increase in the surface roughness (Table 2) wherein Grade
III stage cells showed 4.4-fold increase in surface rough-
ness compared to the control cells. Moreover, the tissue
sections from giant multinucleate cells depicted a marked
increase (24.7-fold) in surface roughness compared to the
control cells as observed in Table 2.
Increase in the cytoskeleton volume of SMAR1 
overexpressing cells
Cancer is a disease that results due to malfunctioning of a
normal cell leading to abnormal proliferation of cells that
ultimately disrupt the tissue organization. The shape and
mechanical rigidity of a cell is determined by the internal
biopolymeric protein scaffolding that constitutes the
essential components of the cell cytoskeleton [31,45,46].
Altered protein structure of cancer cells also modifies the
() Rrms i
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Cells overexpressing SMAR1 exhibit smooth surface mor- phology as shown by SEM images Figure 1
Cells overexpressing SMAR1 exhibit smooth surface 
morphology as shown by SEM images. (A) Images of 
control, SMAR1 and SMAR1-siRNA transfected (transient) 
human embryonic kidney cell line (HEK 293) (photographs 
taken at lower magnification of 3000 × and higher magnifica-
tions of 8,500 × for control and SMAR1-siRNA treated cells 
and 12000 × for SMAR1 treated cells); (B) RT-PCR and (C) 
Western blotting results showing the expression of SMAR1 
in control, SMAR1 and SMAR1-siRNA transfected HEK 293 
cell line wherein actin has been used as the loading control. 
(D) SEM images of control and SMAR1 stably transfected 
mouse melanoma cell line (B16F1) (photographs taken at 
lower magnifications of 1000 × and 3000 ×; and higher mag-
nifications of 8000 × for control and 8,500 × for SMAR1 
treated cells).BMC Cancer 2009, 9:350 http://www.biomedcentral.com/1471-2407/9/350
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shape, rigidity as well as motility of the cells, thus affecting
the cellular cytoskeleton.
Our results show that SMAR1 maintains the cellular mor-
phology that depends upon the underlying cytoskeletal
framework of the cells. Thus, we were interested in detect-
ing differences, between the cytoskeletal volume of con-
trol and SMAR1-overexpressing cells. The cytoskeletons of
control and SMAR1 overexpressing cells were prepared for
AFM study as mentioned in Materials and Methods [44].
Before quantifying the cytoskeletal volume, the topogra-
phy (Fig. 5A) and 3D image (Fig. 5B) of entire cytoskeletal
framework of control cells and cells treated with SMAR1-
P44 peptide was analysed wherein the nucleus appeared
distinct and raised. The topography and profile images of
the cytoskeletal region (excluding the nuclear region)
could be observed (Fig. 5C and 5D) that exhibited pro-
nounced differences between the control and SMAR1-P44
peptide treated cells. The cytoskeletal volume was quanti-
fied by using the free software WSxM by Nanotec Elec-
Mice and human tumor tissue sections exhibit rough surface topography compared to the normal control tissue sections Figure 2
Mice and human tumor tissue sections exhibit rough surface topography compared to the normal control tis-
sue sections. SEM images of (A) tumor sections from nude mice treated with control B16F1 cells (photographs taken at 
lower magnifications of 3,300 × and 4000 × and higher magnification of 12,000 ×) and SMAR1-P44 (photographs taken at lower 
magnification of 3,300 × and 7,500 × and higher magnification of 12,000 ×), (B) sections from human breast cancer cells of dif-
ferent patients. Images from normal breast tissue section and various grades of breast cancer cells: Grade I, Grade II, Grade III 
and giant multinucleate cells are shown. Photographs have been taken at 1000 ×, 3000 × and 8500 × magnification for all the 
tissue sections except for the normal breast tissue as well as Grade I tumor section wherein the highest magnification used was 
27,000 ×.BMC Cancer 2009, 9:350 http://www.biomedcentral.com/1471-2407/9/350
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tronica (version 4.0 develop 3.4). After drying the sample,
the cytoskeleton framework collapses to the surface and it
was assumed that the volume of the collapsed cytoskele-
ton is equivalent to the volume of cytoskeletal fibers and
insoluble components of the endoplasmic reticulum [44].
The calculations of the volume were done over the area
away from the nucleus by first removing any overall tilt of
the image, and then by using "flooding/find hills" option
of the software. For comparing the cytoskeleton of control
HEK 293 cells with that of SMAR1-P44 treated cells,
cytoskeletal volume was normalized by dividing the vol-
ume by the area it occupies (Table 3). Interestingly, we
found that the volume of cellular cytoskeleton (topo-
graphic image shown in Fig. 5E), calculated as mentioned
above, was almost 3.5 times more in SMAR1 overexpress-
ing cells compared to the control cells.
Discussion
Alterations in the physical properties, particularly cell
elasticity, of tissue cells have been recently considered as
an indication of disease [47-49] and thus has evolved as a
phenotypic marker for cellular events associated with cell
adhesion and cytoskeletal organization [47,50-52]. Sev-
eral studies have shown that with increase in metastatic
efficiency in human cancer cell lines, there is a reduction
in the cell stiffness (elasticity) [28-30]. It was also recently
reported that the cell stiffness, measured by force-dis-
placement curves, of metatstatic cancer cells taken from
SMAR1 overexpressing cells exhibit smooth surface profile Figure 3
SMAR1 overexpressing cells exhibit smooth surface profile. AFM images of (A) human embryonic kidney (HEK 293) 
cell line. Height (topography), processed, 3D and profile (of line shown in topography image) of control (x-y range 10 × 10 μm, 
z range 1.8 μm); SMAR1 (x-y range 20 × 20 μm, z range 4.8 μm) and SMAR1-siRNA (x-y range 20 × 20 μm, z range 1.6 μm) are 
shown. (B) AFM images of mouse melanoma (B16F1) cell line. Height, processed, 3D and profile (of line shown in height image) 
of control (x-y range 70 × 70 μm, z range 1.9 μm) and SMAR1 (x-y range 70 × 70 μm, z range 2.8 μm) are shown.BMC Cancer 2009, 9:350 http://www.biomedcentral.com/1471-2407/9/350
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the body (pleural) fluids of patients was softer than the
benign cells lining the body cavity [34].
In this study, we have for the first time studied the topog-
raphy of cells overexpressing SMAR1, a tumor suppressor
protein and compared with the control cells that express
less SMAR1. This protein has been earlier shown to inter-
act with and activate tumor suppressor protein p53, which
in turn activates the downstream effector, p21. This results
into activation of several cell cycle proteins, which ulti-
mately result into retardation of cells at G2/M stage [36].
Since SMAR1 retards tumor growth, we were interested in
investigating its role in the regulation of cell morphology.
Even though it is possible to correlate the shape deforma-
tion with the mechanical or biochemical pathway that
induced the change, an appropriate quantitative morpho-
logical analysis can help in understanding how the modi-
fications take place. We used both AFM and SEM tools to
investigate the topography of cells overexpressing SMAR1.
Interestingly, from both the microscopic studies we found
that SMAR1 induced the cells to exhibit smooth topogra-
phy compared to rough surface profiles of either control
or SMAR1-siRNA treated cells. Experiments were per-
formed on different cell lines as well as on tumor sections
AFM images showing smooth topography in normal tissues compared to the cancerous tissue sections Figure 4
AFM images showing smooth topography in normal tissues compared to the cancerous tissue sections. (A) AFM 
images of tumor sections from nude mice. Height, processed, 3D and profile (of line shown in height image) of tumor sections 
from control (x-y range 20 × 20 μm, z range 1.7 μm) and SMAR1-P44 (x-y range 30 × 30 μm, z range 4.7 μm) treated mice are 
shown. (B) AFM images of human breast cancer sections. Height image and profile (line shown in height image) of tumor sec-
tions from normal breast tissue (x-y range 10 × 10 μm, z range 0.84 μm); Grade I (x-y range 10 × 10 μm, z range 1.17 μm), 
Grade II (x-y range 10 × 10 μm, z range 1.4 μm) and Grade III (x-y range 10 × 10 μm, z range 2.65 μm) tumors and Giant 
multinucleated cells (x-y range 30 × 30 μm, z range 10.8 μm) are shown.BMC Cancer 2009, 9:350 http://www.biomedcentral.com/1471-2407/9/350
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from mice and human breast cancer sections. In all the
cell lines, the control cells exhibited significant surface
roughness compared to SMAR1 overexpressed cells. The
tumor sections from mice injected with B16F1 melanoma
cells also showed rougher surface feature compared to
those treated with SMAR1-P44 peptide. This 44-mer chi-
meric peptide contains 11-mer TAT PTD -domain fused
with 33-mer core region of SMAR1 that retains the tumor
suppressor activity of the full-length protein [42]. Thus,
compared to the cell lines that were transfected with the
full-length SMAR1, even the SMAR1-P44 chimera peptide
was sufficient to impart smooth topography to otherwise
rough control cells. The difference in the surface profile
was more significant in tumor sections obtained from
SMAR1-P44-treated mice, which exhibited a 2-fold
decrease in surface roughness compared to the control
mice. Our results were further validated by using clinical
samples of breast tumor sections obtained from human
patients with different grades of cancer. The tissue sections
demonstrated that in advanced stages of breast cancer
(Grade III) there was a 4.4-fold increase whereas in giant
multinucleate cells, there was an astounding 24.7-fold
increase in the surface roughness compared to the control
cells from normal breast tissue. These results correlate
with the reported observation that with increase in the
grade of cancer in these tissue sections, there is a signifi-
cant reduction in the expression of SMAR1 protein [38].
Thus, with decrease in the expression of SMAR1, the sur-
face roughness of cells increases, thereby implicating the
role of SMAR1 in the regulation of cellular morphology.
Current detection of cancer relies on qualitative morpho-
logical analyses of change in shape of cells that result from
biochemical alterations, such as cytoskeletal remodeling
[53]. In cancerous cells, there is an overall dysregulation
of many proteins including the cytoskeleton proteins
thereby resulting into overall disturbance of cellular archi-
tecture as well as rearrangement of the dynamic structures
involved in cell division and motility [30]. Thus, the
dynamic cytoskeleton reorganization has become impor-
tant with respect to alterations in cell morphology, motil-
ity, adhesion and invasion [54,55]. The cytoskeleton
framework of cells is mainly composed of microfilaments,
microtubules and intermediate filaments, which together
with cell surface receptors and ECM proteins help in regu-
lating cellular morphology. All these proteins together not
only help in maintaining the cell shape but also in cell
adhesion and elongation, thereby organizing the cellular
surface into structural and functional microdomains [56-
59]. Since the cellular morphology is governed by the
underlying cytoskeleton framework, we studied the
cytoskeleton of control as well as SMAR1-overexpressing
cells. Presently, there are three main techniques for study-
ing the cellular cytoskeleton: TEM, immunofluorescence
microscopy, and recently developed, transmission X-ray
microscopy [44]. Besides studying the morphology,
atomic force microscopy is a newer technique that has
been recently used to visualize cellular cytoskeleton as
well [44]. Our AFM data clearly shows a marked increase
in the volume of cellular cytoskeleton in SMAR1 overex-
pressing cells. Interestingly, these results are supported by
cDNA microarray data wherein we have compared the
data of HEK 293 control cells with those treated with
SMAR1-P44 peptide [see Additional file 1, Supplementary
Table S1] as well as control B16F1 cells versus cells stably
Table 1: Weighted mean surface roughness data of control, SMAR1 overexpressing and SMAR1 siRNA treated cells.
Samples Control
Roughness (nm)*,
SMAR1
Roughness (nm)*,
SMAR1-siRNA
Roughness (nm)*,
HEK 293 cell line 49.0154 ± 0.0324 29.6985 ± 0.0533 50.2835 ± 0.0321
B16F1 cell line 132.871 ± 0.00368 97.349 ± 0.0756 -
Mouse Tumor Sections 124.3178 ± 8.3362e-3 62.1869 ± 0.0103
(SMAR1-P44 treated)
-
*The surface areas chosen to calculate the cell surface roughness were 50 × 50 data points for all the cells and tissue sections.   represents 
the weighted mean surface roughness. The values for the surface roughness of the cells were calculated over 4 different cells and are given as the 
weighted mean ± standard deviation
Rrms
WM Rrms
WM Rrms
WM
Rrms
WM
Table 2: Weighted mean surface roughness data of human 
breast tissue sections from normal cells as well as different 
grades of cancer.
Human Breast Tissue Sections
Roughness (nm)*,
Normal 24.6404 ± 0.1254
Grade I 33.8073 ± 0.0467
Grade II 61.4068 ± 0.0118
Grade III 109.0707 ± 2.9733e-3
Giant Multinucleate cells 606.7377 ± 2.8342e-3
*The surface areas chosen to calculate the cell surface roughness 
were 50 × 50 data points for all the tissue sections.   represents 
the weighted mean surface roughness. The values for the surface 
roughness of the cells were calculated over 4 different cells and are 
given as the weighted mean ± standard deviation.
Rrms
WM
Rrms
WMBMC Cancer 2009, 9:350 http://www.biomedcentral.com/1471-2407/9/350
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expressing SMAR1 [GEO Accession Number:
GSM444125; see Additional file 1, Supplementary Table
S2]. We observed that compared to the control cells, genes
particularly coding for the proteins involved in the regula-
tion of cellular architecture were upregulated in cells over-
expressing SMAR1. The microarray data was also
supported by mRNA expression studies in HEK 293 cells
[see Additional file 1, Supplementary Fig S1] that demon-
strated upregulation of specific adhesion proteins such as
neurexin (NEU) as well as cytoskeletal proteins such as
MAP/microtubule affinity-regulating kinase 1 (MARK1)
and Myosin heavy polypeptide 10 (MYH10) in cells over-
expressing SMAR1 compared to either control cells or
those transfected with SMAR1-siRNA. Further, using con-
focal microscopy we observed that SMAR1 overexpres-
sion/knockdown does not affect the expression or
localization of actin and β-tubulin [see Additional file 1,
Supplementary Fig. S2 A and B, respectively] proteins. On
the other hand, SMAR1 overexpression leads to upregula-
tion of fibronectin and vinculin proteins while its knock-
down leads to downregulation of their expression [see
Additional file 1, Supplementary Fig. S2 C and D, respec-
tively]. Taken together, these results imply that the
increased cytoskeletal volume in SMAR1 overexpressing
cells as shown by AFM could be probably due to the
increase in the expression of cytoskeletal proteins. Thus,
SMAR1 seems to restore the defective expression of certain
architectural proteins that may be responsible for impart-
ing smooth topography to otherwise rough cancerous
cells.
Defects in the structure of the cytoskeleton influence a
number of diseases, including different types of tumors
[30]. The response of cells to structural and molecular
SMAR1 overexpression results into increased cytoskeletal volume Figure 5
SMAR1 overexpression results into increased cytoskeletal volume. AFM images of cellular cytoskeleton of HEK 293 
control cells as well as those treated with SMAR1-P44 peptide. Height images of a group of cells (A) and a single cell (B) are 
shown whose 3D (C) is also depicted. Height (D) and profile (E) images of a zoomed area within the single cell are shown in 
both control and SMAR1-P44 treated cells. Using flooding/find hills option of free software WSxM (to calculate the volume of 
the cellular cytoskeleton), the zoomed image showing the volume of cytoskeleton (F) is more in SMAR1-P44 treated cells than 
the control cells.
Table 3: Cytoskeleton volume/area ratio calculated for control versus SMAR1 (P44) peptide treated cells.
HEK 293 cells Flooded Area (A) Flooded Volume (V) Ratio [V/A]
Control 13.4062 μm2 3.9723e+010 Å2 29.63
SMAR1-P44 treated 76.4601 μm2 7.94947e+011 Å2 103.96BMC Cancer 2009, 9:350 http://www.biomedcentral.com/1471-2407/9/350
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alterations induced by the onset and progression of dis-
eases also alter their elastic and viscoelastic properties.
Alterations in cytoskeleton framework of cells are accom-
panied by changes in cell shape and mobility [33,60].
Though our data clearly indicates that SMAR1 modifies
the cellular cytoskeleton that may be responsible for ren-
dering smooth topology to the cells but further molecular
events that induce this potential change in surface rough-
ness need to be explored in detail.
Conclusion
The morphological changes in cell and tissue have
remained the benchmark for cancer diagnosis. Variations
in nucleus size, shape and cell morphology are possibly
related to the functional alterations in cancer cells and
may offer crucial evidence to a particular tumor type and
successful treatment. The powerful imaging tools such as
SEM and AFM are complementary and can provide valua-
ble information about the surface details of cells, particu-
larly cancerous cells. These techniques overlap in their
capabilities to provide nanometer scale lateral informa-
tion, however, deviating from the fact that the AFM can
provide tri-dimensional mapping of the surface resulting
into generation of true topographic data with vertical res-
olution down to the subnanometer range. The high-reso-
lution methods employed in the present work for
investigation of morphological alterations between cells
over- and under-expressing tumor suppressor protein,
SMAR1, provide a method for differentiation between
non-cancerous and cancerous phenotype, respectively.
Thus, in conclusion our studies suggest that smooth cell
surface profile for non-cancerous cells could be attributed
to increased expression of SMAR1 whereas rough cellular
morphology of cancerous cells could be attributed
towards decreased expression of SMAR1 in the latter.
List of abbreviations used
SMAR1: Scaffold/Matrix Associated Region 1 binding pro-
tein; AFM: Atomic Force Microscope; SEM: Scanning Elec-
tron Microscope; HEK 293: human embryonic kidney cell
line; MCF-7: human breast cancer cell line; B16F1: mouse
melanoma cell line.
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